AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
Genentech’s influenza treatment Xofluza (baloxavir marboxil) was granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the regulatory agency.
Amylyx Pharmaceuticals Inc. announced the publication of results from the pivotal CENTAUR trial evaluating AMX0035 – an investigational neuroprotective therapy designed to reduce the death and dysfunction of motor neurons – in people with amyotrophic lateral sclerosis (ALS) in the New England Journal of Medicine.
A new weapon in the war on coronavirus is on the way. Leading health creative agency The Bloc developed SafeCode, a unique device concept which fuses a barcode scanner with UV-C light technology proven to destroy dangerous viruses and bacteria, and is expected to do the same to SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19).
Takeda Pharmaceutical Company Limited announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis, were published in The New England Journal of Medicine (NEJM).
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.
AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.